BioVie Inc. Warrant

BioVie Inc. Warrant is a listed equity derivative that grants the right, but not the obligation, to purchase BioVie Inc. common stock at a preset exercise price within a defined term. Each warrant from the company’s August 2025 unit offering is exercisable at an exercise price of $2.50 per share and carries a five‑year duration from issuance, providing a structured avenue for future capital formation when exercised. The warrant was approved for trading under a dedicated ticker, enabling secondary market price discovery separate from the underlying shares. As a financing tool, it complements BioVie Inc.’s capital strategy by aligning potential future share issuance with investor demand, while giving holders leveraged exposure to the company’s progression as a clinical‑stage biopharmaceutical developer. The instrument’s standardized terms—immediate exercisability, fixed strike, and specified expiry—facilitate transparent valuation and risk management for market participants, and its exchange listing supports liquidity and continuous trading alongside the common equity.